In Vitro Activity of : A New Perspective to Approach Mixed Vaginal Infections?Lactobacillus fermentum: A New Perspective to Approach Mixed Vaginal Infections? LF5 Against Different : A New Perspective to Approach Mixed Vaginal Infections?Candida: A New Perspective to Approach Mixed Vaginal Infections? Species and : A New Perspective to Approach Mixed Vaginal Infections?Gardnerella vaginalis: A New Perspective to Approach Mixed Vaginal Infections?

    loading  Checking for direct PDF access through Ovid

Abstract

Goals:

This study was undertaken to demonstrate the ability of Lactobacillus fermentum LF5 (DSM 32277) to inhibit in vitro different Candida species and Gardnerella vaginalis to weigh its potential effectiveness even in mixed vaginal infections.

Background:

A wide female population is suffering from various vulvovaginal infections. These diseases are often associated with a decrease in the concentration of Lactobacilli in the vagina. Mixed vaginal infections represent >20% of women with vulvovaginal infection.

Study:

LF5 strain was cocultured in De Man, Rogosa and Sharpe with Candida according to a 1:100 ratio in favor of the yeast. Each culture was sampled after 24 hours of incubation for the selective enumeration of the yeasts performed on yeast extract glucose chloramphenicol agar medium.

Study:

The growth of Gardnerella alone (positive control) and in the presence of different concentrations of neutralized supernatants of L. fermentum LF5 ranging from 5% to 20% was quantified by means of optical density at 600 nm (OD600).

Results:

L. fermentum LF5 demonstrated the ability to inhibit significantly the growth of the 5 species of Candida by at least 4 logarithms.

Results:

Furthermore, L. fermentum LF5 showed a significant activity after both 24 and 48 hours (46% and 82% with 20% of neutralized supernatant, respectively). A significant dose-dependent growth inhibition was recorded in particular after 48 hours of incubation, even achieving a 80% inhibition of G. vaginalis growth.

Conclusions:

The biotherapeutic LF5 could be the only documented strain effective in mixed forms. For this purpose, a human clinical trial is in progress.

Related Topics

    loading  Loading Related Articles